Roche eyes FDA filing after bispecific matches Eylea again

Roche’s bispecific faricimab has matched Regeneron’s Eylea in another pair of phase 3 clinical trials. The top-line results suggest the VEGFxAng2 bispecific antibody faricimab performs as well as Eylea in people with “wet” age-related macular degeneration (AMD) even when it is dosed half as often.